Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
Paul Goepfert(University of Maryland, Baltimore), Thomas G. Evans(University of Bristol), Paul Spearman(Cincinnati Children's Hospital Medical Center), Georgia D. Tomaras(National Institutes of Health), Marguerite Koutsoukos(GlaxoSmithKline (Belgium)), Guido Ferrari(Duke University), Clayton Harro(Johns Hopkins University), Beryl A. Koblin(New York Blood Center), Mark Deers(University of Washington), Pierre Vandepapelière(Neovacs (France)), Gérald Voss(Coalition for Epidemic Preparedness Innovations), Sharon E. Frey(St. Louis VA Medical Center), M. Juliana McElrath(Fred Hutch Cancer Center), Lindsey R. Baden(Brigham and Women's Hospital), Helen Horton(New York Blood Center), Louise Pedneault(GlaxoSmithKline (Belgium)), David C. Montefiori(Duke University), William A. Blattner(Unknown), Jonathan D. Fuchs
Cited by 93
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k